A recent retrospective analysis from a subspecialty movement disorder clinic in a US academic medical center reports that a change in diagnosis or medication regimen occurred in 59% of patients within one visit after dopamine transporter imaging [16]. This evidence concerns the gene SLC6A3 and movement disorder.